Dicerna Pharmaceuticals, Inc. (DRNA)

13.79
NASDAQ
Prev Close 13.79
Day Low/High 0.00 / 0.00
52 Wk Low/High 9.31 / 17.98
Exchange NASDAQ
Shares Outstanding 68.27B
Market Cap 941.37M
Div & Yield N.A. (N.A)

Latest News

Interesting DRNA Put And Call Options For May 17th

Interesting DRNA Put And Call Options For May 17th

Investors in Dicerna Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Dicerna™ Announces The Presentation Of Updated Data Demonstrating Utility Of Its Lead Compound DCR-PHXC In Treating Primary Hyperoxaluria Type 1 (PH1) And Type 2 (PH2)

Dicerna™ Announces The Presentation Of Updated Data Demonstrating Utility Of Its Lead Compound DCR-PHXC In Treating Primary Hyperoxaluria Type 1 (PH1) And Type 2 (PH2)

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), (the "Company" or "Dicerna") a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of updated data from its ongoing PHYOX™1 Phase 1...

Dicerna™ Reports Fourth Quarter And Year Ended December 31, 2018 Financial Results And Provides Corporate Update

Dicerna™ Reports Fourth Quarter And Year Ended December 31, 2018 Financial Results And Provides Corporate Update

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and year ended December 31, 2018.

Dicerna To Report Fourth Quarter And Year End 2018 Financial Results And Host Conference Call On March 11, 2019

Dicerna To Report Fourth Quarter And Year End 2018 Financial Results And Host Conference Call On March 11, 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close...

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement...

Dicerna Pharmaceuticals To Present At Upcoming Investor Conferences

Dicerna Pharmaceuticals To Present At Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Hardean E. Achneck, M.D., Vice President, Head Of Medical Development (Photo: Business Wire)

Hardean E. Achneck, M.D., Vice President, Head Of Medical Development (Photo: Business Wire)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the addition of three industry veterans to the Company's management team: This press release features...

Pioneer In Taking RNA Therpeutics Through The Clinic Joins Skyhawk Therapeutics As Chief Medical Officer

Pioneer In Taking RNA Therpeutics Through The Clinic Joins Skyhawk Therapeutics As Chief Medical Officer

Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement...

Dicerna Announces Dosing Of First Volunteer In Phase 1 Clinical Trial Of DCR-HBVS Designed For The Treatment Of Chronic Hepatitis B Virus

Dicerna Announces Dosing Of First Volunteer In Phase 1 Clinical Trial Of DCR-HBVS Designed For The Treatment Of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company") a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the Company's investigational...

Dicerna Evolves Its Board Of Directors To Support Continued Growth

Dicerna Evolves Its Board Of Directors To Support Continued Growth

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced several changes to its board of directors (BOD), including the elevation of J.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved...

First Week Of DRNA February 15th Options Trading

First Week Of DRNA February 15th Options Trading

Investors in Dicerna Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Research Collaboration With Dicerna

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Research Collaboration With Dicerna

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic...

RSI Alert: Dicerna Pharmaceuticals (DRNA) Now Oversold

RSI Alert: Dicerna Pharmaceuticals (DRNA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Dicerna To Join NASDAQ Biotechnology Index

Dicerna To Join NASDAQ Biotechnology Index

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the annual...

Dicerna Announces Closing Of Global Licensing And Research Collaboration With Eli Lilly And Company

Dicerna Announces Closing Of Global Licensing And Research Collaboration With Eli Lilly And Company

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company...

Dicerna Pharmaceuticals Breaks Below 200-Day Moving Average - Notable For DRNA

Dicerna Pharmaceuticals Breaks Below 200-Day Moving Average - Notable For DRNA

In trading on Friday, shares of Dicerna Pharmaceuticals Inc crossed below their 200 day moving average of $13.45, changing hands as low as $13.23 per share. Dicerna Pharmaceuticals Inc shares are currently trading down about 4.7% on the day.

Dicerna To Participate In Citi's 2018 Global Healthcare Conference

Dicerna To Participate In Citi's 2018 Global Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

DRNA Makes Notable Cross Below Critical Moving Average

DRNA Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Dicerna Pharmaceuticals Inc crossed below their 200 day moving average of $13.13, changing hands as low as $12.79 per share. Dicerna Pharmaceuticals Inc shares are currently trading down about 6.5% on the day.

Dicerna To Highlight Lead GalXC™ Pipeline Programs, Collaborations, And Advances To GalXC Technology Platform At R&D Day 2018

Dicerna To Highlight Lead GalXC™ Pipeline Programs, Collaborations, And Advances To GalXC Technology Platform At R&D Day 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.

Dicerna To Participate In Upcoming Investor Conferences

Dicerna To Participate In Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Reports Third Quarter 2018 Financial And Operating Results And Provides Corporate Update

Dicerna Reports Third Quarter 2018 Financial And Operating Results And Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter ended September 30, 2018.

First Week Of December 21st Options Trading For Dicerna Pharmaceuticals (DRNA)

First Week Of December 21st Options Trading For Dicerna Pharmaceuticals (DRNA)

Investors in Dicerna Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Dicerna To Report Third Quarter 2018 Financial Results And Host Conference Call On November 5, 2018

Dicerna To Report Third Quarter 2018 Financial Results And Host Conference Call On November 5, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday,...

Lilly And Dicerna Announce RNAi Licensing And Research Collaboration

Lilly And Dicerna Announce RNAi Licensing And Research Collaboration

- Companies will collaborate on RNAi research for cardio-metabolic, neurodegeneration and pain targets

Dicerna Announces Late-Breaking Data Supporting Use Of DCR-PHXC In Adults With Primary Hyperoxaluria Types 1 And 2 (PH1 And PH2)

Dicerna Announces Late-Breaking Data Supporting Use Of DCR-PHXC In Adults With Primary Hyperoxaluria Types 1 And 2 (PH1 And PH2)

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of late-breaking data from its ongoing PHYOX Phase 1 trial, in which single-dose...

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)